The role of antiangiogenetic agents in the treatment of breast cancer

Current Medicinal Chemistry

Volumn 18, Issue 33, 2011, Pages 5022-5032

  Bareschino, M A ^a,b   Schettino, C ^a,b   Colantuoni, G ^b   Rossi, E ^b   Rossi, A ^b   Maione, P ^b   Ciardiello, F ^a   Gridelli, C ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Breast cancer; Pazopanib; Sorafenib; Sunitinib; Vandetanib; VEGF

Indexed keywords

ANASTROZOLE; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FULVESTRANT; LAPATINIB; NAVELBINE; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CARCINOMA; COMPETITIVE INHIBITION; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; EARLY CANCER; ENZYME ACTIVITY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CANCER; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; METASTASIS; METASTATIC BREAST CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEINURIA; QT PROLONGATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PACLITAXEL; PROTEIN KINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80054873093     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797636072     Document Type: Article

References (108)

1. Porter, P.L.Global trends in breast cancer incidence and mortality. Salud Publica Mex., 2009, 51, 141-146.
2. Kamanga, F.; Dores, G.M.; Anderson, W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol., 2006, 24, 2137-2150. (Pubitemid 46655601)
3. Slamon, D.J.; Romond, E.H.; Perez, E.A. Advances in adjuvant therapy for breast cancer. Clin. Adv. Hematol. Oncol., 2006, 4, 4-9.
4. Lorusso, V. Bevacizumab in the treatment of HER2-negative breast cancer. Biologic, 2008, 2, 813-821.
5. Gennari, A.; Conte, P.; Rosso, R.; Orlandini, C.; Bruzzi, P. Survival of metastatic breast carcinoma patients over a 20 year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer, 2005, 104,1742-1750. (Pubitemid 41437440)
6. Kerbel, R.S. Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science. 2006, 26, 1171-1175. (Pubitemid 43801134)
7. Shibuya, M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell. Struct. Funct., 2001, 26, 25-35. (Pubitemid 32421949)
8. Hicklin, D.J.; Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol ., 2005, 23,1011-1027. (Pubitemid 46202320)
9. Hayes, D.F.; Miller, K.; Sledge, G. Angiogenesis as targeted breast cancer therapy. Breast., 2007,16, S17-S19.
10. Marty, M.; Pivot, X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur. J. Cancer. 2008, 44, 912-920.
11. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9, 669-676. (Pubitemid 36749215)
12. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med., 1999, 77, 527-543. (Pubitemid 29426311)
13. Mura, M.; Dos Santos, C.C.; Stewart, D.; Liu, M. Vascular endothelial growth factor and related molecules in acute lung injury. J. Appl. Physiol., 2004, 97,1605-1617. (Pubitemid 39425973)
14. Ferrara, N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int., 1999, 56, 794-814. (Pubitemid 29411709)
15. Ikeda, E.; Achen, M.G.; Breier, G.; Risau, W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem., 1995, 270, 19761-19766.
16. Rak, J.; Mitsuhashi, Y.; Bayko, L.; Filmus, J.; Shirasawa, S.; Sasazuki, T.; Kerbel, R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res., 1995, 55, 575-580.
17. Ferrara, N. Vascular endothelial growth factor. Trends Cardiovasc. Med., 1993, 3, 244-250. (Pubitemid 23321872)
18. Kaipainen, A.; Korhonen, J.; Mustonen, T.; Van Hinsbergh, V.W.; Fang, G.H.; Dumont, D.; Breitman, M.; Alitalo, K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA, 1995, 92, 3566-3570.
19. Brown, L.F.; Berse, B.; Jackman, R.W.; Tognazzi, K.; Guidi, A.J.; Dvorak, H.F.; Senger, D.R.; Connolly, J.L.; Schnitt, S.J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol., 1995, 26, 86-91.
20. Pavlakis, K.; Messini, I.; Vrekoussis, T.; Yiannou, P.; Keramopoullos, D.; Louvrou, N.; Liakakos, T.; Stathopoulos, E.N. The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions. B.M.C. Cancer. 2008, 8, 88.
21. Foekens, J.A.; Peters, H.A.; Grebenchtchikov, N.; Look, M.P.; Meijer-van Gelder, M.E.; Geurts-Moespot, A.; van der Kwast, T.H.; Sweep, C.G.; Klijn, J.G. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res., 2001, 61, 5407-5414. (Pubitemid 32694919)
22. Gasparini, G.; Toi, M.; Miceli, R.; Vermeulen, P.B.; Dittami, R.; Biganzoli, E.; Morabito, A.; Fanelli, M.; Gatti, C.; Suzuki, H.; Tominaga, T.; Dirix, L.Y.; Gion, M. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J. Sci. Am., 1999, 5,101-111. (Pubitemid 29169299)
23. Linderholm, B.; Grankvist, K.; Wilking, N.; Johansson, M.; Tavelin, B.; Henriksson R.; Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. , 2000, 18, 1423-1431. (Pubitemid 30205387)
24. Geng, L.; Donnelly, E.; McMahon, G.; Lin, P.C.; Sierra- Rivera, E.; Oshinka, H.; Hallahan, D.E. Inhibition of vascular endothelial growth factor receptor signalling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001, 61, 2413-2419. (Pubitemid 32685816)
25. Ferrara, N.; Hillan ,K.J.; Gerber, H.P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov.,2004, 3, 391-400. (Pubitemid 38618122)
26. Presta, L.G.; Chen, H.; O'Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57, 4593-4599. (Pubitemid 27441066)
27. Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, LL; Tong RT; Chung. D.C; Sahani, D.V.; Kalva, S.P.; Kozin, S.V.; Mino, M.; Cohen, K.S.; Scadden, D.T.; Hartford, A.C.; Fischman, A.J.; Clark, J.W.; Ryan, D.P.; Zhu, A.X.; Blaszkowsky, L.S.; Chen, H.X.; Shellito, P.C.; Lauwers, G.Y.; Jain, R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 2004,10, 145-147. (Pubitemid 38524883)
28. Baluk, P.; Hashizume, H.; McDonald, D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev., 2005, 15, 102-111. (Pubitemid 40127638)
29. Gordon, M.S.; Margolin, K.; Talpaz, M.; Sledge, G.W. Jr; Holmgren, E.; Benjamin, R.; Stalter, S.; Shak, S.; Adelman, D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001,19, 843-850. (Pubitemid 32119100)
30. Margolin, K.; Gordon, M.S.; Holmgren, E.; Gaudreault, J.; Novotny, W.; Fyfe, G.; Adelman, D.; Stalter, S.; Breed. J. Phase I b trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-termsafety data. J. Clin. Oncol. 2001, 19,851-856. (Pubitemid 32119101)
31. Cobleigh, M.A.; Langmuir, V.K.; Sledge, G.W.; Miller, K.D.; Haney, L.; Novotny, W.F.; Reimann, J.D.; Vassel, A. A phase I/II dose escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol., 2003,30, 117-124. (Pubitemid 37433402)
32. Burstein, H.J.; Parker, L.M.; Savoie, J.; Younger, J.; Kuter, I.; Ryan, P.D.; Garber, J.E.; Campos, S.M.; Shulman, L.N.; Harris, L.N.; Gelman, R.; Winer, E. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat, 2002, 76 (Suppl 1), abstr 446.
33. Miller, K.; Gradishar, W.; Moish, C. ; Sledge, G. Capecitabine Capecitabine plus bevacizumab in fi rst line metastatic breast cancer: An interim safety and efficacy report of the fi rst phase of Xeloda plus Avastin 1st line metastatic breast cancer trial. Breast Cancer Res. Treat., 2006, 100 (Suppl 1), abstr. 2068.
34. Perez, E.A.; Hillman, D.W.; Kugler, J.W.; Steen, P.D.; Fitch, T.R.; Rowland, K.M.: North Central cancer treatment group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Breast Cancer Res. Treat., 2006, 100 (Suppl 1), abstr. 2069.
35. Ramaswamy, B.; Elias, A.D.; Kelbick, N.T.; Dodley, A.; Morrow, M.; Hauger, M.; Allen, J.; Rhoades, C.; Kendra, K.; Chen, H.X.; Eckhardt, S.G.; Shapiro, C.L. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res., 2006,12, 3124-3129. (Pubitemid 43837360)
36. Miller, K.D.; Chap, L.I.; Holmes, F.A.; Cobleigh, M.A.; Marcom, P.K.; Fehrenbacher, L.; Dickler, M.; Overmoyer, B.A.; Reimann, J.D.; Sing, A.P.; Langmuir, L.; Rugo, H.S.; Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol., 2005, 23, 792-799. (Pubitemid 46224178)
37. Relf, M.; LeJeune, S.; Scott, P.A.; Fox, S.; Smith, K.; Leek, R.; Moghaddam, A.; Whitehouse, R.; Bicknell, R.; Harris, A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fi broblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res., 1999, 57, 963-969. (Pubitemid 27098025)
38. Miller, K.D.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med., 2007, 357, 2666-2676.
39. Miles, D.; Chan, A.; Romieu, G.; Dirix, L.; Cortés, J.; Pivot, X.; Tomczak, P.; Juozaityte, E.; Harbeck, N.; Steger, G. Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC). Cancer Res., 2009, 69 (suppl 24), abstr.41.
40. Robert, N.J.; Dieras, V.; Glaspy, J.; Brufsky, A.; Bondarenko, I.; Lipatov, O.; Perez, E.; Yardley, D.; Zhou, X.; Phan, S. RIBBON-1: Randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J. Clin. Oncol., 2009, 27 (15S), abstr. 1005.
41. Dieras, V.; Glaspy, J.; Brufsky, A.; Bondarenko, I.; Lipatov, O.; Perez, E.A.; Chan, S.; Zhou, X.; Phan, S.C.; Robert, N. Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) Eur. J. Cancer, 2009,45 (suppl 2), abstr. PD-5016.
42. Brufsky, A.; Bondarenko, I.; Smirnov, V.; Hurvitz, S.; Perez, E.; Ponomarova, O.; Vynnychenko, I.; Swamy, R.; Mu, H.; Rivera, R. RIBBON- 2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. Cancer Res., 2009, 69 (suppl 24), abstr. 42.
43. Cortes-Funes, H.; Pritchard, K.I.; Biganzoli, L.; Thomssen, C.; Pierga, J.; Koza,; I. A. Kwong; Kellokumpu-Lehtinen, P.; Chlistalla, A.; Smith, I. Multinational study (n=2041) of first-line bevacizumab (Bev) plus taxanebased chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Updated results of MO19391. Eur. J. Cancer, 2009, 45 (suppl 2), abstr. PD-5017.
44. Miller, K.D; O'Neill, A.; Perez ,E. A; Seidman, A. D.; Sledge, G. W. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph nodepositive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104) J. Clin. Oncol., 2008, 26 (20S), abstr. 520.
45. Clinicaltrials.gov. Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer. Available at: Http://clinicaltrials.gov/ct2/ show/NCT00433511
46. Clinical trials.gov BEATRICE Study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer. Available at: Http://clinicaltrials.gov/ct2/show/NCT00528567
47. Lyons, J. A.; Silverman, P.; Remick, S.; Chen, H.; Leeming, R.; Shenk, R.; Fu, P.; Dumadag, L.; Escuro, K.; Overmoyer. B. Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer. J. Clin. Oncol., 2006, 24 (18S), abstr. 3049.
48. Greil, R.; Moik, M.; Reitsamer. R.; Ressler. S.; Stoll, M.; Namberger. K.; Menzel, C.; Mlineritsch, B. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. Eur. J. Surg. Oncol. 2009, 10,1048-1054.
49. Hurvitz, S. A.; Bosserman, L. D.; Leland-Jones, B.; Thirwell, M.; Allison, M. K.; Barstis, J.; Molthrop, D.; Quan, E.; Upadhyaya, G.; Slamon, D. A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer. J. Clin. Oncol., 2008, 26 (15S), abstr. 562.
50. Rastogi, P.; Buyse, M.; Swain, S.; Jacobs, S.; Robidoux, A.; Liepman, M.; Dy, P.; Geyer C. Jr.; Wolmark N. Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group. J. Clin. Oncol., 2009, 27 (15S), abstr. 584.
51. Clinicaltrials.gov. Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery. Available at http://clinicaltrials.gov/ct2/show/NCT00408408.
52. Laquente, B.; Viñals, F.; Germà, J.R. Metronomic chemotherapy: An antiangiogenic scheduling. Clin. Transl. Oncol., 2007, 9, 93-98.
53. Khosvari, P.; Perez-Manga, G. Una nueva strategia terapeutica en el cancer de mama: Quimioterapia metronomic. AN. Med. Interna, 2007, 24, 261-262.
54. Gasparini, G. Metronomic scheduling: The future of chemotherapy? Lancet Oncol., 2001, 2, 733-740. (Pubitemid 33134058)
55. Emmenegger, U.; Kerbel, R.S. Five years of clinical experience with metronomic chemotherapy: Achievements and perspectives. Onkologie, 2007, 30, 606-608. (Pubitemid 350247758)
56. Orlando, L.; Cardillo, A.; Rocca, A.; Balduzzi, A.; Ghisini, R.; Peruzzotti, G.; Goldhirsch. A.; D'Alessandro. C.; Cinieri, S.; Preda, L.; Colleoni, M. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drug., 2006, 17, 961-967. (Pubitemid 44350615)
57. Burstein, H.J.; Spiegel, D.; Kindsvogel, K.; Parker, L.M.; Bunnell, C.A.; Partridge, A.H.; Come, S.E.; Ryan, P.D.; Gelman, R.; Winer, E.P Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study. Breast Cancer Res. Treat., 2005, 94 (Suppl 1), abstr. 4.
58. Dellapasqua, S.; Bertolini, F.; Bagnardi, V.; Campagnoli. E.; Scarano, E.; Torrisi, R.; Shaked, Y.; Mancuso, P.; Goldhirsch, A.; Rocca, A.; Pietri, E.; Colleoni, M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol., 2008, 26, 4899-4905.
59. Konecny, G.E.; Meng, Y.G.; Untch, M.; Wang, H.J.; Bauerfeind, I.; Epstein, M.; Stieber, P.; Vernes, J.M.; Gutierrez, J.; Hong, K.; Beryt, M.; Hepp, H.; Slamon, D.J.; Pegram, M.D. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin. Cancer Res., 2004,10, 1706-1716. (Pubitemid 38435562)
60. Scheuer, W.; Friess, T.; Hasmann, M. Enhanced antitumour effect by combination of HER2-targeting antibodies with bevacizumab in a human breast cancer xenograft model. Eur. J. Cancer, 2006, 66, (suppl 4), abstr. 213.
61. Pegram, M.D.; Yeon, C.; Ku, N.C.; Gaudreault, J.; Slamon, D.J. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res. Treat., 2004, 88, (suppl 124), abstr. 3039.
62. Pegram, M.; Chan, D.; Dichmann, R.A.; Tan-Chiu, E.; Yeon, C.; Durna, L.; Lin, L.S.; Slamon, D. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res. Treat., 2006, 100 (Suppl 1), abstr. 301.
63. Clinicaltrials.gov. First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU. Available at http://clinicaltrials.gov/ct2/show/ NCT00520975.
64. Clinicaltrials.gov. A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00391092.
65. Rugo, H. S.; Franco, S.; Munster, P.; Stopeck, A.; Ma, W.; Lyandres, J.; Lahiri, S.; Arbushites, M.; Koehler, M.; Dickler, M. N. A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). J. Clin. Oncol., 2008, 26 (15S), abstr. 1042.
66. G. S. Falchook, S. Moulder, J. J. Wheler, A. Naing, D. Hong, C. Ng, E. Jackson, Y. Jiang, R. Kurzrock; Combination trastuzumab, lapatinib, and bevacizumab in HER2+ breast cancer and other malignancies. 2009, Breast Cancer Symposium Proceedings, abstr. 244.
67. Kedar, D.; Baker, C.H.; Killion, J.J.; Dinney, C.P.; Fidler, I.J. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 2002, 8, 3592-3600. (Pubitemid 35340738)
68. Jung, Y.D.; Mansfield, P.F.; Akagi, M.; Takeda, A.; Liu, W.; Bucana, C.D.; Hicklin, D.J.; Ellis, L.M. Effects of combination antivascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur. J. Cancer, 2002, 38, 1133-1140. (Pubitemid 34468020)
69. Rugo, H.; Dickler, M.; Scott, J.; Moore, D.H.; Park, J.W. Circulating endothelial cell (CEC) and tumor cell (CTC) analysis in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC). Breast Cancer Res. Treat., 2004, 88 (suppl 142), abstr. 3088
70. Dickler, M.N.; Rugo, H.S.; Eberle, C.A., Brogi, E.; Caravelli, J.F.; Panageas, K.S.; Boyd, J.; Yeh, B.; Lake, D.E.; Dang, C.T.; Gilewski, T.A., Bromberg, J.F.; Seidman, A.D.; D'Andrea, G.M.; Moasser, M.M.; Melisko, M.; Park, J.W.; Dancey, J.; Norton, L.; Hudis, C.A. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin. Cancer Res., 2008, 14, 7878-7883.
71. Clinical trials.gov. BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab. Available at http://clinicaltrials.gov/ct2/show/NCT00625898.
72. Clinical trials.gov. A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto). Available at http://clinicaltrials.gov/ct2/show/NCT00567554.
73. Von Minckwitz, G.; Bauerfeind, I. Gerber, B.; Eidtmann,H.; Kaufmann, M.; Costa, S.D.;Loibl, S.; Nekljudova, V.; Untch, M. Geparquinto: An interim safety analysis of epirubicin/cyclophosphamide followed by docetaxel with or without bevacizumab as neoadjuvant chemotherapy for primary breast cancer patients. J. Clin. Oncol., 2009, 27 (15S), abstr e11519.
74. Adams, J.; Carder, P.J.; Downey, S.; Forbes, M.A.; MacLennan, K.; Allgar, V.; Kaufman, S.; Hallam, S.; Bicknell, R.; Walker, J.J.; Cairnduff, F.; Selby, P.J.; Perren, T.J.; Lansdown, M.; Banks, R.E. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res., 2000, 60, 2898-2905. (Pubitemid 30395813)
75. Garvin, S.; Dabrosin, C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res., 2003, 63, 8742-8748. (Pubitemid 38064052)
76. Albrecht, E.D.; Aberdeen, G.W.; Niklaus, A.L.; Babischkin, J.S.; Suresch, D.L.; Pepe, G.J. Acute temporal regulation of vascular endothelial growth/permeability factor expression and endothelial morphology in the baboon endometrium by ovarian steroids. J. Clin. Endocrinol. Metab., 2003, 88, 2844-2852. (Pubitemid 36724466)
77. Traina, T.A.; Rugo, H.; Caravelli, J.; Yeh, B.; Panageas, K.; Bruckner, L.; Norton, L.; Park, J.; Hudis, C.; Dickler, M. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J. Clin. Oncol., 2006, 24 (18S), abstr. 3050.
78. Yardley, D.A.; Peacock, N.; Arrowsmith, E.; Harwin, W.; Miletello, G.; Raefsky, E.; Shipley, E.; Spigel, D.R.; Hanson, S.; Greco, F.A. Preliminary safety results from a multicenter phase II non comparative two arm pilot of bevacizumab with anastrazole or fulvestrant as 1 sl line metastatic breast cancer therapy. Cancer Res., 2008, 69, abtrs. 4113.
79. Forero-Torres, A.; Galleshaw, J.; Jones, C.; Percent, I.; Nabell, L.; Carpenter, J.; Falkson, C.; Krontiras, H.; Bland, K.; De Los Santos, J.; Saleh M.N. A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. J. Clin. Oncol., 2008, 26 (15S), abstr. 625.
80. Clinicaltrials.gov. Tamoxifen or letrozole with or without bevacizumab in treating women with stage III or stage IV breast cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00601900.
81. Clinicaltrials.gov. BEVACIZUMAB + LETROZOL vs. LETROZOL as first line treatment in postmenopausal patients with advanced or metastatic breast cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00545077.
82. Chow, L.Q., Eckhardt, S.G. Sunitinib: From rational design to clinical efficacy. J. Clin. Oncol., 2007, 25, 884-896. (Pubitemid 350002890)
83. Abrams, T.J.; Murray, L.J.; Pesenti, E.; Holway, V.W.; Colombo, T.; Lee, L.B.; Cherrington, J.M.; Pryer, N.K. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Molecular Cancer Therapeutics., 2003, 2, 1011-1021.
84. Burstein, H.J.; Elias, A.D.; Rugo, H.S.; Cobleigh, M.A.; Wolff, A.C.; Eisenberg, P.D.; Lehman, M.; Adams, B.J.; Bello, C.L.; DePrimo, S.E.; Baum, C.M.; Miller, K.D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol., 2008, 26, 1810-1816.
85. Kozloff, M.; Chuang, E.; Starr, A,; Gowland, P.A.; Cataruozolo, P.E.; Collier, M.; Verkh, L.; Huang, X.; Kern, K.A.; Miller, K. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann. Onc., 2009, Dec 23. [Epub ahead of print].
86. Barrios, C.; Liu, M.C.; Lee, S.C.; Vanlemmens, L.; Ferrero, J.; Tabei, T.; Pivot, X.; Iwata, H,; Aogi, K.; Brickman, M,; Zhang, K.; Kern, K.; Martin, M. Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C)in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC). Cancer Res., 2009, 69 (suppl 24), abstr. 46.
87. Press release. Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer. Available at http//www.pfizer.com.
88. Tryfonopoulos, D.; O'Donovan, N.; Clynes, M.; Crown, J. P. Preclinical evaluation of sunitinib, alone and in combination with trastuzumab, in HER2 positive breast cancer (BC). J. Clin. Oncol., 2008, 26 (15S), abstr. 14689.
89. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P,; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A., Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64, 7099-7109. (Pubitemid 39331023)
90. Bianchi, G.; Loibl, S., Zamagni, C.; Ardizzoni, A.; Raab, G.; Siena, S.; Wolf, C.; Westermeier, T.; Bergamin, L. A phase II multicentre uncontrolled trial of sorafenib (BAY43-9006) in patients with metastatic breast cancer. Eur. J. Cancer., 2005, 3, (suppl 78), abstr. 276.
91. Moreno-Aspitia, A.; Hillman, D.W.; Wiesenfeld, M.; Hobday, T.J.; Rowland, K.M.; Northfelt, D.W.; Tenner, K.S.; Palmieri, F.M.; Perez, E.A. BAY43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J. Clin. Oncol., 2006, 24 (18S), abstr.577.
92. Baselga, J.; Segalla, J.G.M.; Roché, J. H.; Del Giglio, A.; Ciruelos, E.M.; Cabral Filho, S.; Gomez, P.; Lluch, A.; Llombart, A.; Costa, F. SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv). Eur. J. Cancer, 2009,45, (suppl 2), abstr. 3LBA.
93. Gradishar, W.J.; Kaklamani, V.; Prasad Sahoo, T.; Lokanatha, D.; Raina, V.; Bondarde, S.; Jain, M.; Schwartzberg, L. A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer. Cancer Res., 2009, 69 (suppl 24), abstr. 44.
94. Isaacs, C.; Wilkinson, M.; Liu, M.C.; Ottaviano, Y.; Chung, G.; Warren, R.; Jennifer, E.W.; Cohen, P.; Smith, K.L.; Novielli, A.; Castle, J.; Slack, R. Phase II Study of Sorafenib with Anastrozole To Overcome Resistance to Aromatase Inhibitors (AIs) in Patients with Hormone Receptor Positive (ER/PR+) AI Resistant Metastatic Breast Cancer (MBC). Cancer Res., 2009, 69 (suppl 24), abstr.3090.
95. Wedge, S.R.; Ogilvie, D.J.; Dukes, M.; Kendrew, J.; Chester, R.; Jackson, J.A.; Boffey, S.J.; Valentine, P.J.; Curwen, J.O.; Musgrove, H.L.; Graham, G.A.; Hughes, G.D.; Thomas, A.P.; Stokes, E.S.; Curry, B. Richmond, G.H., Wadsworth, P.F.; Bigley, A.L.; Hennequin, L.F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res., 2002, 62, 4645-4655.
96. Ciardiello, F.; Caputo, R.; Damiano, V.; Caputo, R.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B.M.; Fontanini, G.; Bianco, A.R.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res., 2003, 9, 1546-1556. (Pubitemid 36418413)
97. Miller, K.D.; Trigo, J.M.; Wheeler, C.; Barge, A.; Rowbottom, J.; Sledge, G.; Baselga, J.A. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res., 2005, 11, 3369-3376. (Pubitemid 40627889)
98. Boer, K.; Lang, I.; Llombart-Cussac, A.; Andreasson, I.; Vivanco, G.L.; Sanders, N.; Pover, G.M.; Murray, E. Vandetanib with docetaxel as secondline treatment for advanced breast cancer: A double-blind, placebo controlled, randomized phase II study. Breast Cancer Res. Treat. 2007, 106 (suppl 1) abstr. 6081.
99. Clinical trials.gov. A Randomised, Double-Blind, Parallel- Group, Multicentre, Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/Daily or Placebo) With Fulvestrant (Loading Dose), In Postmenopausal Advanced Breast Cancer Patients. Available at http://clinicaltrials.gov/ct2/show/NCT00752986.
100. Inai, T.; Mancuso, M.; Hashizume, H.; Baffert, F.; Haskell, A.; Baluk, P.; Hu-Lowe, D.D.; Shalinsky, D.R.; Thurston, G.; Yancopoulos, G.D.; McDonald, D.M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Path., 2004, 165, 35-52. (Pubitemid 38821812)
101. Rugo, H.S.; Stopeck, A.; Joy, A.A., Chan, S.; Verma, S.; Lluch, A.; Liau, K.F.; Kim, S.; Bycott, P.; Soulieres, D. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). J. Clin. Oncol., 2007, 25 (18S), abstr. 1003.
102. Kumar, R.; Knick, V.B.; Rudolph, S.K.; Johnson, J.H.; Crosby, R.M.; Crouthamel, M.C.; Hopper, T.M.; Miller, C.G.; Harrington, L.E.; Onori, J.A.; Mullin, R.J.; Gilmer, T.M.; Truesdale, A.T.; Epperly, A.H.; Boloor, A.; Stafford, J.A.; Luttrell, D.K.; Cheung, M. Pharmacokinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther., 2007, 6, 2012-2021. (Pubitemid 47052491)
103. Slamon, D.; Gomez, H.L.; Kabbinavar, F.F.; Amit, O.; Richie, M.; Pandite, L.; Goodman, V. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer. J. Clin. Oncol., 2008, 26 (15S), abstr. 1016.
104. Taylor, S.K.; Chia, S.; Dent, S.; Clemons, M.; Grenci, P.; Wang, L.; Oza, A.M.; Ivy, P.; Pritchard, K.; Leighl, N. A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium. J. Clin. Oncol., 2009, 27 (15S), abstr. 1133.
105. Clinical trials.gov. A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-expressing Inflammatory Breast Cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00558103.
106. Polverino, A.; Coxon, A.; Starnes, C.; Diaz, Z.; DeMelfi, T.; Wang, L.; Bready, J.; Estrada, J.; Cattley, R.; Kaufman, S.; Chen, D.; Gan, Y.; Kumar, G.; Meyer, J.; Neervannan, S.; Alva, G.; Talvenheimo, J.; Montestruque, S.; Tasker, A.; Patel, V.; Radinsky, R.; Kendall, R. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res., 2006, 66, 8715-8721. (Pubitemid 44449188)
107. Coxon, A.; Bush, T.; Saffran, D.; Kaufman, S., Belmontes, B.; Rex, K.; Hughes, P.; Caenepeel, S.; Rottman, J.B.; Tasker, A.; Patel, V.; Kendall, R.; Radinsky, R.; Polverino, A. Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors. Clin. Cancer Res., 2009, 15, 110-118.
108. Mackey, J.; Hurvitz, S.; Crown, J.; Forbes, J., Roché, H.; Pinter, T.; Eiermann, W.; Kennedy, M.J.; Priou, F.; Provencher, L.; Adrover, E.; Pienkowski, T., Houé V, Rupin M, Martin M CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC). Cancer Res., 2009, 69 (suppl 24), abstr. 47.